Clinical trials sponsored by Shanghai Pharmaceuticals Holding Co., Ltd

Phase breakdown

Conditions studied

Recruiting trials led by Shanghai Pharmaceuticals Holding Co., Ltd

• A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
  NCT06434597 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Clinical Study of T3011 in Subjects With Advanced Melanoma
  NCT06214156 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
  NCT05872347 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 25 locations
• Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
  NCT05860465 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 22 locations

Common questions

How many trials is Shanghai Pharmaceuticals Holding Co., Ltd recruiting for?

Shanghai Pharmaceuticals Holding Co., Ltd is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.